Tag: innovation

XRP cloud mining platform offers both fixed returns and crypto appreciation amid renewed investor interest

TALLINN, Estonia, July 19, 2025 (GLOBE NEWSWIRE) -- With the cryptocurrency market facing renewed volatility, investors are seeking solid opportunities with long-term potential. Bitcoin Solaris (BTC-S), an emerging blockchain project, is capturing attention for all the right reasons. As it nears the end of its presale phase, Bitcoin Solaris offers a guaranteed launch price of $20—positioning itself as a secure and forward-looking investment in uncertain times.

Why Bitcoin Solaris Stands Out from the Rest

Retail investors gain first-of-its-kind on‑chain access to early‑stage private equity in nuclear micro‑reactors

BROOKLYN, New York , July 19, 2025 (GLOBE NEWSWIRE) -- LTESocks.io, a leading provider of high-performance mobile proxy solutions, today announced its ambitious 2025 technology roadmap designed to build the next generation of network infrastructure for its global client base. The multi-phase initiative focuses on fundamentally enhancing speed, reliability, and scalability by integrating cutting-edge protocols and expanding its state-of-the-art 5G network.

A groundbreaking innovation in XRP mining has arrived—PFMCrypto introduces a cloud-based, daily-yield model that redefines passive income opportunities within the XRP ecosystem.

TORONTO, July 18, 2025 (GLOBE NEWSWIRE) -- Purpose Investments Inc. (“Purpose”) is pleased to announce distributions for the month of July 2025 for its open-end exchange traded funds and closed-end funds (“the Funds”).

TORONTO, 18 juill. 2025 (GLOBE NEWSWIRE) -- Purpose Investments Inc. (« Purpose ») a le plaisir d’annoncer des distributions pour le mois de de juillet 2025 pour ses fonds négociés en bourse à capital variable et ses fonds à capital fixe (les « Fonds »).

SAN CARLOS, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on July 17, 2025 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 138,190 shares of Iovance’s common stock to 20 new, non-executive employees.